Date: November 07, 2025
Ref. No.: KDL/SE/074/2024-25

To, **BSE Limited** **Corporate Relationship Department** 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 **Scrip Code:** 543328	To, **National Stock Exchange of India Limited** Exchange Plaza, Plot No. C-1, Block G, Bandra Kurla Complex, Bandra (East) Mumbai – 400051 **NSE Symbol:** KRSNAA

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for Investor Presentation.

Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a copy of the presentation for the Investors/Analysts on Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2025.

Request you to take the same on your records.

Thanking you,
Yours sincerely,

For **Krsnaa Diagnostics Limited**

Sujoy Sudipta Bose
Digitally signed by Sujoy Sudipta Bose
Date: 2025.11.07 20:08:43 +05'30'

Krsnaa Diagnostics Limited

Sujoy Sudipta Bose
Company Secretary & Compliance Officer
Encl: as above

krsnaa DIAGNOSTICS
LET'S DO GOOD...

Q2 FY2026
Result Presentation

One of **INDIA'S LARGEST** Integrated Diagnostic Service Provider





Disclaimer

This presentation contains statements that are “forward-looking statements”, including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements pertaining to Krsnaa Diagnostics’ future business developments and economic performance. While these forward-looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations.

These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance.

Krsnaa Diagnostics undertakes no obligation to publicly revise any forward-looking statements to reflect future/ likely events or circumstances.

© Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2025



Krsnaa Diagnostics Limited

Krsnaa DIAGNOSTICS
LET'S DO GOOD...

Krsnaa Diagnostics At a Glance

186
CT/ MRI Centres

120
Pathology Labs

3,500+
Patient Collectionn Centres

18
States/UT
Presence in India

75 Million+
Patients Served Since Inception

Krsnaa Diagnostics is one of the **fastest growing and Integrated diagnostic service provider** which includes radiology, pathology and tele-radiology


Provides **quality** and inclusive diagnostic services at **affordable rates** across various segments with a focus on Public Private Partnership model


One of India's largest NABH accredited tele-radiology reporting hub with inherent capability & capacity to process X-rays, CT scans and MRI scans, serving patients at remotest locations


The workforce comprises **350+ radiologists**, **120+ pathologists**, and **3,000+ qualified professionals,** including clinicians, technicians and operators


© Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2025

Retail Dynamics









"Q-o-Q Retail Business Revenue Increased By 60%"

© Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2025

Q2 FY26 Financial Performance

Achieved All-Time High Quarterly PAT of INR 239 Mn, Rising 22% Y-o-Y on Strengthening Margins and Operating Leverage

Particulars	Q2 FY26	Q2 FY25	Growth
Revenue	2,060	1,863	11%
EBIDTA	602	509	18%
EBIDTA Margin	29%	27%	221 bps
PAT	239	196	22%
PAT Margin	12%	11%	111bps


Particulars	Q2 FY26	Q2 FY25	Growth
EPS	7.3	5.9	24%
No. of Patient Served	5.4	5.2	4%
No. of Test performed	16.4	17.1	(4%)
NABL Accreditation (Pathology lab)	57	37	54%
NABH Accreditation (Radiology Centre)	36	24	50%


INR in mn except EPS, NABL & NABH


© Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2025

Q2 FY26 – Centre Growth


Radiology









Pathology







Upon completion of our existing order book, we will have **200+ CT/MRI** centres, cementing our position as one of **Asia's Largest Radiology Players.**

The Rajasthan project will grow our network to **7** Reference Labs, **41** Mother Labs, **249** Satellite Labs & **5,000+** Collection Centres — making us **India's Deeply Rooted** and **Widely Accessible** Pathology Service Provider.

© Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2025



Competitive Advantages

Driving Excellence Through Quality

American College of Radiology™

India's 1st ACR Accredited Company

India's 1st CAP Accredited Lab at Government Facility

India's 1st NABH Accredited Tele-Radiology Hub

Service Excellence Pioneers of Indian Diagnostic Industry

© Krsnaa Diagnostics Ltd. All Rights Reserved.
Copyright 2025

Driving Excellence Through Quality

57



National Accreditation for Board of testing's & Calibration Laboratories

36



National Accreditation Board for Hospitals & Healthcare Providers

We are committed to delivering superior quality as our benchmark and proudly served **~5.4 mn patients** in Q2 FY26, driven by our continuous focus on excellence.


© Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2025

Our Strengths

The only listed company in PPP (Public Private Partnership) space with bid win ratio of 75%+

18 states and union territories with penetration till tier-II and tier-III towns

~75 Mn+ patients served since inception



Integrated diagnostic services available for 24/7 and 365 days, Radiology, Pathology, and Teleradiology

Quality diagnostic services at most affordable prices (~70% lower than the peers)

Operationalizing retail presence in 4 states

Krsnaa has redefined what's possible in diagnostics — proving that we can deliver radiology services at prices up to 70% lower than market, in a **capital-intensive business, and still generate margins** on par with the industry's best. **This isn't a low-price government contract story — it's a high-efficiency, high-impact model built to scale.**

© Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2025

Our Pricing - “Everyone Can Afford”

Segment	Test	Competition 1	Competition 2	Competition 3	Krsnaa	% lower from competitors
Radiology	CT Brain	4,500	4,500	3,500	880	(75)%
Radiology	MRI Brain	8,000	8,250	7,000	1,340	(81)%
Pathology	CBC	250	250	200	37	(82)%
Pathology	Blood Sugar	85	80	70	20	(71)%
Pathology	Thyroid	500	550	550	55	(90)%
Pathology	Vitamin D	1,500	1,250	1,450	153	(89)%
Pathology	Vitamin B12	1,000	1,100	1,300	69	(95)%
Pathology	HbA1C	550	440	400	49	(88)%


By offering services at **over 70% below** market rates, Krsnaa Diagnostics is expanding access to millions across India — and still growing faster than the industry, proving that **scale, efficiency, and impact can go hand in hand.**


Note:
Amounts are in INR.
Above mentioned examples from our comprehensive test lists for illustration purpose only and referenced from publicly available information

© Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2025

Presence - PAN India

Well Diversified Regional Revenue Mix





India map for representation only, not to scale

© Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2025



New Centres

State-Of-Art Infrastructure Enabling Reliable Diagnostics

Soon to be operationalized AI-Enabled MRI Centres



Amravati, Maharashtra



Buldhana, Maharashtra

Actual centre images

© Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2025

State-Of-Art Infrastructure Enabling Reliable Diagnostics

Soon to be Operationalized Low Radiation CT Scan Centres



Ranchi, Jharkhand



Tuljapur, Maharashtra

Actual centre images

© Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2025



Financial Performance

Consolidated Financial Performance

Particulars	Q2 FY 26		Q2 FY 25		Q1 FY 26		H1 FY 26		H1 FY 25	
	Amount	%	Amount	%	Amount	%	Amount	%	Amount	%
Revenue from operations	**2,060**		**1,863**		**1,930**		**3,990**		**3,566**	
Expenses										
Cost of Material Consumed	481	23%	449	24%	474	25%	955	24%	878	25%
Employee benefits expense	348	17%	339	18%	350	18%	698	18%	660	19%
Fees to hospitals and others	170	8%	174	9%	154	8%	324	8%	297	8%
Other expenses	459	22%	392	22%	428	22%	887	22%	780	22%
Total Expenses	1,458	71%	1,354	73%	1,406	73%	2,864	72%	2,615	73%
EBITDA Before CSR & ESOP	**602**	**29%**	**509**	**27%**	**524**	**27%**	**1,126**	**28%**	**951**	**27%**
CSR and ESOP	10	1%	15	1%	10	1%	20	1%	30	1%
EBITDA	**592**	**29%**	**494**	**26%**	**514**	**27%**	**1,106**	**28%**	**921**	**26%**
Less: Finance costs	82	4%	64	3%	63	3%	145	4%	117	3%
Less: Depreciation	236	11%	222	12%	216	11%	452	11%	437	12%
Add: Other income	42	2%	46	2%	40	2%	82	2%	119	3%
PBT	**316**	**15%**	**254**	**14%**	**275**	**14%**	**591**	**15%**	**486**	**14%**
Tax	77	4%	58	3%	69	4%	146	4%	111	3%
PAT	**239**	**12%**	**196**	**11%**	**205**	**11%**	**445**	**11%**	**375**	**11%**

In mn

© Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2025

Consolidated Financial Performance

(INR In Mn)

Assets	Sep 30, 2025	Mar 31, 2025
Non-current assets		
Property, plant and equipment	6,800.17	6,674.34
Capital work-in-progress	302.05	29.63
Intangible assets	26.65	29.49
Financial assets		
Investments	315.61	315.42
Other financial assets	719.94	1,182.77
Deferred tax asset (net)	34.58	33.33
Other non-current assets	1,101.39	406.25
Total non-current assets	**9,300.39**	**8,671.23**
Current assets		
Inventories	314.89	294.76
Financial assets		
Trade receivables	3,582.79	2,777.45
Cash and cash equivalents	105.60	38.46
Bank balances other than cash and cash equivalent	1,193.65	645.90
Other financial assets	297.82	282.89
Other current assets	271.77	105.26
Total current assets	**5,766.52**	**4,144.72**
Total Assets	**15,066.91**	**12,815.95**

Liabilities	Sep 30, 2025	Mar 31, 2025
Equity		
Equity share capital	162.19	161.45
Other equity	9,067.36	8,666.25
Total equity	**9,229.55**	**8,827.70**
Liabilities		
Non-current liabilities		
Borrowings	538.00	185.04
Lease Liabilities	350.96	286.52
Other financial liabilities	583.43	208.29
Employee benefit obligations	35.53	28.61
Deferred Tax Liabilities	254.81	225.91
Other non-current liabilities	-	-
Total non-current liabilities	**1,762.73**	**934.37**
Current liabilities		
Financial liabilities		
Borrowings	1,846.76	1470.38
Lease Liabilities	121.68	93.33
Trade payables	1,396.46	971.27
Other financial liabilities	505.76	371.14
Other current liabilities	59.83	54.17
Provision	63.72	55.77
Current Tax Liabilities (net)	80.42	37.82
Current liabilities	**4,074.63**	**3,053.88**
Total Liabilities	**5,837.36**	**3988.25**
Total Equity and Liabilities	**15,066.91**	**12,815.95**

For further information please contact

Krsnaa Diagnostics

Vivek Jain, Head- Investor Relations

head.investor@krsnaa.in

Contact: +91 74107 00645

https://krsnaadiagnostics.com